December 11, 2023
“Johnson & Johnson on Tuesday forecast revenue growth of 5% to 6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara… The company expects full-year adjusted operational… Continue Reading…
Recent Comments